Kunapuli Padmaja, Chitta Kasyapa S, Cowell John K
Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York, NY 14263, USA.
Oncogene. 2003 Jun 26;22(26):3985-91. doi: 10.1038/sj.onc.1206584.
The leucine-rich, glioma-inactivated (LGI1) gene, located in 10q24, was originally identified because it was interrupted and inactivated by a reciprocal chromosome translocation in the T98G glioma cell line. Loss of LGI1 expression in high-grade brain tumors is correlated with the frequent loss of chromosome 10 during progression of gliomas. To investigate whether this gene can suppress the malignant phenotype in glioma cells, we introduced the LGI1 gene into cells that do (U87) and do not (T98G and A172) express LGI1 endogenously. A172 and T98G cells showed a significant reduction in cell proliferation potential as a result of re-expression of LGI1, whereas U87 cells did not. Using BD matrigel matrix chamber assays we were also able to show that the migration ability of the reconstituted A172 and T98G cells was also reduced considerably. Finally, these reconstituted T98G and A172 cells showed a significant reduction in the ability to form colonies in soft agar compared with the parental cells. This analysis clearly demonstrates that re-expression of the LGI1 gene in glioma cells that were null for its activity can greatly reduce their malignant potential. These observations provide the opportunity to investigate the role of LGI1 in gliomagenesis and, since LGI1 is predicted to be a membrane-bound protein, potentially provides the opportunity to develop novel treatment strategies for malignant gliomas.
富含亮氨酸的胶质瘤失活基因(LGI1)位于10q24,最初是因为它在T98G胶质瘤细胞系中被相互染色体易位中断并失活而被鉴定出来。高级别脑肿瘤中LGI1表达的缺失与胶质瘤进展过程中10号染色体的频繁缺失相关。为了研究该基因是否能抑制胶质瘤细胞的恶性表型,我们将LGI1基因导入内源性表达LGI1的细胞(U87)和不表达LGI1的细胞(T98G和A172)中。由于LGI1的重新表达,A172和T98G细胞的细胞增殖潜能显著降低,而U87细胞则没有。使用BD基质胶基质小室试验,我们还能够证明重组后的A172和T98G细胞的迁移能力也大大降低。最后,与亲代细胞相比,这些重组后的T98G和A172细胞在软琼脂中形成集落的能力显著降低。该分析清楚地表明,在其活性缺失的胶质瘤细胞中重新表达LGI1基因可大大降低其恶性潜能。这些观察结果为研究LGI1在胶质瘤发生中的作用提供了机会,并且由于LGI1预计是一种膜结合蛋白,可能为开发恶性胶质瘤的新治疗策略提供机会。